tradingkey.logo
tradingkey.logo
Search

Dermata Therapeutics Inc

DRMA
Add to Watchlist
1.185USD
+0.005+0.42%
Close 07-31 16:00ETQuotes delayed by 15 min
4.77MMarket Cap
LossP/E TTM

DRMA Income Statement

You can find the annual or quarterly income statement of Dermata Therapeutics Inc here for insights into the performance and operational efficiency of Dermata Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Operating expenses
-17.67%1.93M
-40.62%1.90M
-45.42%1.76M
-38.53%1.77M
-26.96%2.34M
44.17%3.20M
78.02%3.23M
66.46%2.88M
40.65%3.20M
29.69%2.22M
-25.92%1.81M
-36.55%1.73M
-18.25%2.28M
-32.95%1.71M
42.86%2.45M
105.31%2.73M
23.18%2.79M
419.48%2.55M
217.05%1.71M
67.76%1.33M
67.72%2.26M
--491.43K
--540.06K
--792.79K
--1.35M
R&D expenses
-70.05%383.72K
-75.98%526.62K
-79.00%504.39K
-69.25%617.84K
-19.97%1.28M
93.13%2.19M
165.94%2.40M
139.48%2.01M
34.22%1.60M
27.65%1.14M
-41.87%902.98K
-47.97%838.93K
-25.27%1.19M
-20.01%889.36K
94.22%1.55M
85.95%1.61M
134.48%1.60M
872.69%1.11M
563.90%799.78K
110.51%867.20K
-29.19%680.59K
--114.30K
--120.47K
--411.95K
--961.10K
Depreciation, depletion, and amortization
--0.00
----
--0.00
--0.00
--0.00
----
----
--0.00
--0.00
----
----
----
--0.00
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
--0.00
--322.00
Operating profit
17.67%-1.93M
40.62%-1.90M
45.42%-1.76M
38.53%-1.77M
26.96%-2.34M
-44.17%-3.20M
-78.02%-3.23M
-66.46%-2.88M
-40.65%-3.20M
-29.69%-2.22M
25.92%-1.81M
36.55%-1.73M
18.25%-2.28M
32.95%-1.71M
-42.86%-2.45M
-105.31%-2.73M
-23.18%-2.79M
-419.48%-2.55M
-217.05%-1.71M
-67.76%-1.33M
-67.72%-2.26M
---491.43K
---540.06K
---792.79K
---1.35M
Net non-operating interest income (expenses)
Non-operating interest income
117.24%78.68K
--38.51K
--68.68K
--71.64K
--36.22K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-98.86%651.00
-93.68%1.82K
-40.58%43.13K
--38.48K
--57.33K
--28.86K
--72.60K
Special income (expenses)
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
----
----
----
--133.59K
----
----
----
Income before tax
19.79%-1.85M
40.91%-1.86M
46.68%-1.69M
39.87%-1.70M
26.50%-2.30M
-47.66%-3.15M
-84.57%-3.17M
-66.28%-2.83M
-39.91%-3.13M
-27.81%-2.13M
29.09%-1.72M
37.69%-1.70M
19.60%-2.24M
34.60%-1.67M
-41.55%-2.42M
-105.03%-2.73M
-20.88%-2.79M
-544.15%-2.55M
-186.73%-1.71M
-62.09%-1.33M
-62.18%-2.30M
---396.31K
---597.39K
---821.65K
---1.42M
Income after tax
19.79%-1.85M
40.91%-1.86M
46.68%-1.69M
39.87%-1.70M
26.50%-2.30M
-47.66%-3.15M
-84.57%-3.17M
-66.28%-2.83M
-39.91%-3.13M
-27.81%-2.13M
29.09%-1.72M
37.69%-1.70M
19.60%-2.24M
34.60%-1.67M
-41.55%-2.42M
-105.03%-2.73M
-20.88%-2.79M
-544.15%-2.55M
-186.73%-1.71M
-62.09%-1.33M
-62.18%-2.30M
---396.31K
---597.39K
---821.65K
---1.42M
Net income from continuous operations
19.79%-1.85M
40.91%-1.86M
46.68%-1.69M
39.87%-1.70M
26.50%-2.30M
-47.66%-3.15M
-84.57%-3.17M
-66.28%-2.83M
-39.91%-3.13M
-27.81%-2.13M
29.09%-1.72M
37.69%-1.70M
19.60%-2.24M
34.60%-1.67M
-41.55%-2.42M
-105.03%-2.73M
-20.88%-2.79M
-544.15%-2.55M
-186.73%-1.71M
-62.09%-1.33M
-62.18%-2.30M
---396.31K
---597.39K
---821.65K
---1.42M
Net income attributable to controlling interests
19.79%-1.85M
40.91%-1.86M
46.68%-1.69M
39.87%-1.70M
26.50%-2.30M
-47.66%-3.15M
-84.57%-3.17M
-66.28%-2.83M
-39.91%-3.13M
-27.81%-2.13M
29.09%-1.72M
37.69%-1.70M
19.60%-2.24M
67.36%-1.67M
43.29%-2.42M
-105.03%-2.73M
-20.88%-2.79M
-1190.67%-5.12M
-615.63%-4.28M
-62.09%-1.33M
-62.18%-2.30M
---396.31K
---597.39K
---821.65K
---1.42M
Preferred share dividend
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--2.56M
--2.56M
----
----
----
----
----
----
Net income attributable to common shareholders
19.79%-1.85M
40.91%-1.86M
46.68%-1.69M
39.87%-1.70M
26.50%-2.30M
-47.66%-3.15M
-84.57%-3.17M
-66.28%-2.83M
-39.91%-3.13M
-27.81%-2.13M
29.09%-1.72M
37.69%-1.70M
19.60%-2.24M
67.36%-1.67M
43.29%-2.42M
-105.03%-2.73M
-20.88%-2.79M
-1190.67%-5.12M
-615.63%-4.28M
-62.09%-1.33M
-62.18%-2.30M
---396.31K
---597.39K
---821.65K
---1.42M
Basic earnings per share
89.29%-0.48
20.06%-1.65
19.24%-1.65
-296.30%-16.57
36.69%-4.47
69.15%-2.06
74.76%-2.04
55.68%-4.18
79.29%-7.06
79.44%-6.68
82.94%-8.09
83.88%-9.43
57.42%-34.08
77.96%-32.48
76.99%-47.40
-52.53%-58.54
-20.53%-80.06
-1190.79%-147.40
-1096.72%-206.02
-62.10%-38.38
-62.18%-66.42
---11.42
---17.22
---23.68
---40.95
Diluted earnings per share
89.29%-0.48
20.06%-1.65
19.24%-1.65
-296.30%-16.57
36.69%-4.47
69.15%-2.06
74.76%-2.04
55.68%-4.18
79.29%-7.06
79.44%-6.68
82.94%-8.09
83.88%-9.43
57.42%-34.08
77.96%-32.48
76.99%-47.40
-52.53%-58.54
-20.53%-80.06
-1190.79%-147.40
-1096.72%-206.02
-62.10%-38.38
-62.18%-66.42
---11.42
---17.22
---23.68
---40.95
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Dermata Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing DRMA stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Dermata Therapeutics Inc's net income for the year?

Dermata Therapeutics Inc posted -7.56M in net income for fiscal year 2025.

How much net income did Dermata Therapeutics Inc post in the last quarter?

Dermata Therapeutics Inc reported -1.85M in net income for the latest quarter。

What was Dermata Therapeutics Inc's annual operating profit?

Dermata Therapeutics Inc's operating income was -7.77M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.